Management of Type IV Hypersensitivity Reactions

Clinical Presentation and Management

The American Society of Clinical Oncology recommends stopping exposure to the offending agent immediately for patients experiencing Type IV hypersensitivity reactions 1, 2
For Grade 1/2 reactions, the European Society of Medical Oncology suggests slowing or temporarily stopping infusion if drug-related, and providing symptomatic treatment 1, 2
The National Comprehensive Cancer Network recommends stopping treatment completely and implementing aggressive symptomatic therapy for Grade 3/4 reactions 1, 2
Corticosteroids are the mainstay of treatment for Type IV hypersensitivity reactions, with a recommended equivalent dose to 1-2 mg/kg of IV (methyl)prednisolone every 6 hours for severe reactions 3
Antihistamines, such as H1 antagonists (e.g., diphenhydramine 50 mg IV) and H2 antagonists (e.g., ranitidine 50 mg IV or cimetidine 300 mg IV), may be used in addition to corticosteroids 3
Desensitization protocols may be considered for patients who need to continue therapy with platinum-based chemotherapy drugs 1, 2
Premedication with corticosteroids plus antihistamines is recommended before administration of taxanes 1, 2
Monitoring vital signs until complete resolution of symptoms and observing for at least 24 hours for severe reactions is crucial 3
Documenting the reaction in detail to guide future medication choices and considering referral to an allergist/immunologist for comprehensive evaluation and management planning is recommended 4